DNA-MVA Vaccine Generates Strong Immune Response Against Leukemia-Specific Peptide HA-1
A DNA prime-boost vaccination strategy produced one of the strongest peptide-specific CD8+ T cell responses ever recorded against the leukemia-associated antigen HA-1, with cytotoxic activity lasting over 12 months.
Quick Facts
What This Study Found
Seven of nine donors developed HA-1-specific CD8+ T cell responses up to 1.5% of total CD8+ repertoire after DNA-MVA prime-boost vaccination, with strong cytotoxic activity and responses detectable at 12 months.
Key Numbers
9 donors; 7 responders; up to 1.5% of CD8+ repertoire; >12 month responses; TRBV7-9 TCR conservation; strong cytotoxic activity against HA-1-expressing targets
How They Did This
Phase I clinical study. Nine HA-1-negative donors received 2-3 DNA priming vaccinations followed by modified vaccinia Ankara (MVA) boost. T cell responses measured by flow cytometry, cytotoxicity assays, and TCR repertoire analysis over 12 months.
Why This Research Matters
Boosting anti-leukemia immune responses through vaccination could reduce relapse after stem cell transplant, which currently occurs in many patients despite otherwise successful transplantation.
The Bigger Picture
Peptide-targeted vaccines for cancer immunotherapy are gaining traction. This study demonstrates that mHAg peptides can generate exceptionally strong immune responses, potentially complementing checkpoint inhibitors and CAR-T therapy for blood cancers.
What This Study Doesn't Tell Us
Small study (9 donors). Vaccination was in healthy donors, not leukemia patients. Clinical anti-leukemia efficacy not tested. The approach requires HLA-matched donors who are HA-1 negative, limiting the eligible population.
Questions This Raises
- ?Would vaccinating leukemia patients post-transplant boost their graft-versus-leukemia response and reduce relapse?
- ?Can this vaccination approach be extended to other mHAg peptides beyond HA-1?
- ?Could the vaccinated donor T cells be transferred to patients as an adoptive cell therapy?
Trust & Context
- Key Stat:
- 1.5% of CD8+ T cells One of the strongest primary peptide-specific T cell responses ever recorded to a DNA-MVA prime-boost regimen
- Evidence Grade:
- Moderate evidence: Phase I clinical study with strong immunological results in 9 donors, but no clinical efficacy data against leukemia. Small sample size.
- Study Age:
- Published in 2021. mHAg-targeted vaccination strategies continue to be explored in clinical settings.
- Original Title:
- DNA and modified vaccinia Ankara prime-boost vaccination generates strong CD8+ T cell responses against minor histocompatibility antigen HA-1.
- Published In:
- British journal of haematology, 195(3), 433-446 (2021)
- Authors:
- Eldershaw, Suzy A, Pearce, Hayden, Inman, Charlotte F, Piper, Karen P, Abbotts, Ben, Stephens, Christine, Nicol, Samantha, Croft, Wayne, Powell, Richard, Begum, Jusnara, Taylor, Graham, Nunnick, Jane, Walsh, Donna, Sirovica, Mirjana, Saddique, Shamyla, Nagra, Sandeep, Ferguson, Paul, Moss, Paul, Malladi, Ram
- Database ID:
- RPEP-05364
Evidence Hierarchy
Frequently Asked Questions
What is HA-1 and why target it for leukemia?
HA-1 is a minor histocompatibility antigen — a small protein difference between people that the immune system can recognize. It is expressed on blood-forming tissue, making it an ideal target for immune cells to attack remaining leukemia cells after a stem cell transplant.
How does this vaccine work?
The vaccine uses a two-step "prime-boost" approach: DNA injections first teach the immune system to recognize the HA-1 peptide, then a modified vaccinia virus boost amplifies the response, generating large numbers of killer T cells that can find and destroy cells displaying HA-1.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-05364APA
Eldershaw, Suzy A; Pearce, Hayden; Inman, Charlotte F; Piper, Karen P; Abbotts, Ben; Stephens, Christine; Nicol, Samantha; Croft, Wayne; Powell, Richard; Begum, Jusnara; Taylor, Graham; Nunnick, Jane; Walsh, Donna; Sirovica, Mirjana; Saddique, Shamyla; Nagra, Sandeep; Ferguson, Paul; Moss, Paul; Malladi, Ram. (2021). DNA and modified vaccinia Ankara prime-boost vaccination generates strong CD8+ T cell responses against minor histocompatibility antigen HA-1.. British journal of haematology, 195(3), 433-446. https://doi.org/10.1111/bjh.17495
MLA
Eldershaw, Suzy A, et al. "DNA and modified vaccinia Ankara prime-boost vaccination generates strong CD8+ T cell responses against minor histocompatibility antigen HA-1.." British journal of haematology, 2021. https://doi.org/10.1111/bjh.17495
RethinkPeptides
RethinkPeptides Research Database. "DNA and modified vaccinia Ankara prime-boost vaccination gen..." RPEP-05364. Retrieved from https://rethinkpeptides.com/research/eldershaw-2021-dna-and-modified-vaccinia
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.